HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC), as a highly lethal malignancy with high mortality, lacks of effective treatment. Canonical therapeutic targets in PDAC demand further verification among which HER2 receptor tyrosine kinase inhibitor pyrotinib as treatment targets has not be decide...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Tiebo, Zhang, Xiaofei, Xu, Haiyan, Zhang, Xiao, Ge, Weiyu, Li, Shumin, Ma, Jingyu, Yue, Ming, Xue, Shengbai, Cui, Jiujie, Wang, Liwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714091/
https://www.ncbi.nlm.nih.gov/pubmed/36457011
http://dx.doi.org/10.1186/s12935-022-02807-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714091/
https://www.ncbi.nlm.nih.gov/pubmed/36457011
http://dx.doi.org/10.1186/s12935-022-02807-4

Ejemplares similares